<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01716988</url>
  </required_header>
  <id_info>
    <org_study_id>NL39246.042.12</org_study_id>
    <nct_id>NCT01716988</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Micafungin in Critically Ill Patients</brief_title>
  <official_title>Pharmacokinetics of Micafungin in Critically Ill Patients With Invasive Candidiasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study of micafungin in ICU versus non-ICU patients showed a significantly lower treatment
      success in ICU patients compared with non-ICU patients. It is known that in critically ill
      patients, alterations in function of various organs and body systems can influence the
      pharmacokinetics and hence the plasma concentration of a drug. The pharmacokinetic parameters
      of micafungin in critically ill patients are most likely different, but this has not been
      specifically studied.

      The pharmacokinetic parameters of micafungin in critically ill patients will be established
      and plasma concentrations of micafungin will be correlated with disease severity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of pharmacokinetic parameters/plasma concentrations of micafungin with disease severity.</measure>
    <time_frame>4 days</time_frame>
    <description>Correlation of the level of micafungin concentration with disease severity scores. Correlation of pharmacokinetic parameters (clearance, half-life) of micafungin with disease severity scores.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of micafungin in ICU patients.</measure>
    <time_frame>4 days</time_frame>
    <description>Calculate the pharmacokinetic parameters (clearance, half life, volume of distribution) of micafungin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time (in days) to culture conversion.</measure>
    <time_frame>max 28 days</time_frame>
    <description>Number of days untill cultures are negative.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of the plasma concentration of micafungin with response to treatment.</measure>
    <time_frame>max 28 days</time_frame>
    <description>Correlation of the level of micafungin concentration with outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of the plasma concentration of micafungin with inflammation parameters.</measure>
    <time_frame>4 days</time_frame>
    <description>Correlation of the level of micafungin concentration with interleukin-6, interleukin-8 and procalcitonin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC)/minimal inhibitory concentration (MIC) ratio.</measure>
    <time_frame>max 28 days</time_frame>
    <description>Area under the concentration-time curve of micafungin devided by the minimal inhibitory concentration of the candida species.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composing a pharmacokinetic model of micafungin in critically ill patients.</measure>
    <time_frame>max 28 days</time_frame>
    <description>Composing a pharmacokinetic model of micafungin to estimate the 24-hours AUC of micafungin based on limited samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Highest observed plasma concentration (Cmax)/minimal inhibitory concentration (MIC) ratio.</measure>
    <time_frame>28 days</time_frame>
    <description>Highest observed plasma concentration of micafungin devided by the minimal inhibitory concentration of the candida species.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">19</enrollment>
  <condition>Critical Illness</condition>
  <condition>Invasive Candidiasis</condition>
  <arm_group>
    <arm_group_label>Micafungin</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with invasive candidiasis admitted to an intensive care unit.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment with micafungin.

          -  Admission to an ICU.

          -  Age â‰¥ 18 years.

          -  Invasive candidiasis.

        Exclusion Criteria:

          -  Blood sampling not possible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2012</study_first_submitted>
  <study_first_submitted_qc>October 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2012</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Jan-Willem C Alffenaar</investigator_full_name>
    <investigator_title>PharmD, PhD</investigator_title>
  </responsible_party>
  <keyword>Micafungin</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>invasive candidiasis</keyword>
  <keyword>intensive care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidiasis, Invasive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Micafungin</mesh_term>
    <mesh_term>Echinocandins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

